Table 3. Echocardiographic data of DN-EGFR or CT mice after 2 weeks of aldosterone treatment (NAS).
| CT sham | CT NAS | DN-EGFR sham | DN-EGFR NAS | |
| n | 6 | 5 | 5 | 5 |
| Body Weight (g) | 24±0.8 | 24.1±0.5 | 23.8±0.9 | 24±0.6 |
| Age (day) | 68±4 | 67±3 | 65±2 | 71±3 |
| Heart rate (bpm) | 506±12 | 474±9 | 537±15 | 470±25 |
| Cardiac and vascular remodelling | ||||
| Diastolic Ao (mm) | 1.36±0.04 | 1.25±0.05 | 1.3±0.08 | 1.32±0.05 |
| LA (mm) | 2.47±0.05 | 2.51±0.12 | 2.37±0.1 | 2.7±0.11 |
| LV EDD/BW (mm/g) | 0.16±0.01 | 0.15±0.005 | 0.16±0.01 | 0.15±0.003 |
| LV mass/BW (mg/g) | 4.14±0.35 | 4.49±0.2 | 5.0±0.23 | 4.17±0.20 |
| LV Systolic function | ||||
| EF (%) | 90±2 | 87±3 | 83±3 | 85±2 |
| Vcfc (circ/s) | 3.46±0.17 | 2.99±0.19 | 2.9±0.25 | 2.66±0.11 |
| Sa (cm/s) | 2.52±0.28 | 2.74±0.08 | 2.51±0.09 | 2.34±0.16 |
| Spw (cm/s) | 3.06±0.16 | 2.48±0.12 | 3.08±0.17 | 2.41±0.14* |
| LV Diastolic function | ||||
| IVRT (ms) | 16±0.56 | 20.4±1.54* | 17±1.2 | 19±1.04* |
| Ea (cm/s) | 4.6±0.45 | 4.59±0.21 | 4.63±0.12 | 4.04±0.23 |
| Epw (cm/s) | 4.27±0.25 | 4.78±0.27 | 5.1±0.29 | 4.44±0.32 |
| E/Ea | 22.8±1.52 | 21.8±0.64 | 22.1±1.25 | 26.5±2.2 |
LA: left atrium; LV EDD: left ventricle end diastolic diameter; BW: body weight; EF: ejection fraction; Vcfc: velocity shortening of circumferential fibers; Sa, Spw: maximal systolic velocity of the mitral annulus and posterior wall; IVRT: isovolumic relaxation time; Ea and Epw: maximal diastolic velocity of the mitral annulus and the posterior wall; E: maximal velocity of the LV inflow.
*p<0.05 versus CT-Sham.